about
Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genesNuclear translocation of β-catenin during mesenchymal stem cells differentiation into hepatocytes is associated with a tumoral phenotypeA high level of liver-specific expression of oncogenic Kras(V12) drives robust liver tumorigenesis in transgenic zebrafishInvolvement of DNA damage response pathways in hepatocellular carcinoma.SAMD9L inactivation promotes cell proliferation via facilitating G1-S transition in hepatitis B virus-associated hepatocellular carcinoma.Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo.Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss.Disruption of tumor suppressor gene Hint1 leads to remodeling of the lipid metabolic phenotype of mouse liver.Targeted p21WAF1/CIP1 activation by RNAa inhibits hepatocellular carcinoma cells.Targeted deletion of hepatocyte Ikkbeta confers growth advantages.COMMD7 is correlated with a novel NF-κB positive feedback loop in hepatocellular carcinoma.Aflatoxin B1 inhibits the type 1 interferon response pathway via STAT1 suggesting another mechanism of hepatocellular carcinomaAbsence of p53 gene expression in selenium molecular prevention of chemically induced hepatocarcinogenesis in rats.FXR-Gankyrin axis is involved in development of pediatric liver cancer.The downregulation of ErbB3 binding protein 1 (EBP1) is associated with poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.Roles for rat hepatocyte malignant transforming factor (HMTF) in late stage of hepatocarcinogenesis.CI431, an Aqueous Compound from Ciona intestinalis L., Induces Apoptosis through a Mitochondria-Mediated Pathway in Human Hepatocellular Carcinoma Cells.Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention.Activation of PERK-Nrf2 oncogenic signaling promotes Mdm2-mediated Rb degradation in persistently infected HCV culture.NAT10 is upregulated in hepatocellular carcinoma and enhances mutant p53 activity.Novel therapeutic approaches for hepatocellulcar carcinoma: fact and fiction.Quantitative methylation analysis reveals gender and age differences in p16INK4a hypermethylation in hepatitis B virus-related hepatocellular carcinoma.RNA Binding Protein CUGBP1 Inhibits Liver Cancer in a Phosphorylation-Dependent Manner.Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells.Interplay of miRNAs and Canonical Wnt Signaling Pathway in Hepatocellular Carcinoma.PARP1 activation increases expression of modified tumor suppressors and pathways underlying development of aggressive hepatoblastomaUpdate in global trends and aetiology of hepatocellular carcinoma
P2860
Q26772317-DD7ECB9B-BA73-4CF4-B602-229629DBF4AFQ27305074-BA69B01C-6814-4E37-8E72-9A35D630BAE2Q28393439-F014D195-6796-4F42-80C7-39D95BDD39F9Q33616812-02B87F78-CE96-4616-816E-25144A46F855Q33970149-42F08DC0-93AD-462A-A1E8-2601137E1625Q35138721-87D6038A-89A2-4E6F-B128-6777572E2D84Q35613285-B8464BAC-644C-4EB5-9F93-562A5321E06AQ36196812-B3D7B701-6BD1-4DA3-95C6-B545CA2F2016Q36297935-7C88B76F-ADCA-4E1A-82F6-098D9AEF90FEQ37144753-E5BA8DBA-A26C-4833-AF3E-9D1783ABD12DQ37362756-546A9615-1299-4C33-A1C6-ED72E28BC1CEQ37713659-6F1807CA-AF6A-4BA7-A3CF-0874741EAB76Q38548673-460426DF-31EF-40AF-9104-FF84D1825A9FQ38768973-C6363E47-1E37-4C16-A47F-8F06E5D88FF7Q38969791-455281D5-EC7C-4311-96E4-9172703FFAB3Q39470843-BA770CE0-5408-41C2-99FC-19A427AC9A90Q39486026-26E9D029-3341-4227-B58B-C18E403D4A62Q39917877-75A27AC0-6A75-45C3-A351-611AC8A6936FQ40072826-5E2A36F2-BD90-40A2-87D0-EAF161F1C71BQ41585790-489F05DA-E776-448F-8527-D8A897362652Q43112701-CF4D28DD-9F43-471F-855C-E9C130FA7487Q45360884-0C725D7A-F330-4AC0-AA17-D259EE8E616AQ50970430-17750E5B-A018-4D0D-9CF5-E7437F8F8242Q54652252-21084421-0E1E-4405-88D7-08C23ADF2324Q55417805-45637AC7-5130-4640-A11D-5E48AE2D4883Q57144042-56C77BC1-67C2-4BF9-991B-D066C98A2C65Q59136659-A4551347-C191-4C43-AF9F-38122B13C972
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Tumor suppressor and hepatocellular carcinoma
@ast
Tumor suppressor and hepatocellular carcinoma
@en
Tumor suppressor and hepatocellular carcinoma
@nl
type
label
Tumor suppressor and hepatocellular carcinoma
@ast
Tumor suppressor and hepatocellular carcinoma
@en
Tumor suppressor and hepatocellular carcinoma
@nl
prefLabel
Tumor suppressor and hepatocellular carcinoma
@ast
Tumor suppressor and hepatocellular carcinoma
@en
Tumor suppressor and hepatocellular carcinoma
@nl
P2860
P3181
P356
P1476
Tumor suppressor and hepatocellular carcinoma
@en
P2093
Jean-Francois Dufour
Juliette Martin
P2860
P304
P3181
P356
10.3748/WJG.14.1720
P407
P577
2008-03-21T00:00:00Z